Colistin Resistance in Carbapenem-Resistant Klebsiella pneumoniae: Laboratory Detection and Impact on Mortality

Clinical Infectious Diseases

Volumn 64, Issue 6, 2017, Pages 711-718

  Rojas, Laura J ^a,b,c   Salim, Madiha ^d   Cober, Eric ^a   Richter, Sandra S ^e   Perez, Federico ^b,c   Salata, Robert A ^b   Kalayjian, Robert C ^f   Watkins, Richard R ^g,h   Marshall, Steve ^c   Rudin, Susan D ^a,c   Domitrovic, T Nicholas ^a,c   Hujer, Andrea M ^a,c   Hujer, Kristine M ^a,c   Doi, Yohei ⁱ   Kaye, Keith S ^d   Evans, Scott ^j   Fowler, Vance G ^h,k   Bonomo, Robert A ^a,b,c   Van Duin, David ^l  

^a Department of Medicine ^*  (United States)

^b CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c LOUIS STOKES CLEVELAND VA MEDICAL CENTER   (United States)

^d WAYNE STATE UNIVERSITY   (United States)

^e LERNER RESEARCH INSTITUTE   (United States)

^f METROHEALTH MEDICAL CENTER   (United States)

^g Northeastern Ohio Medical University   (United States)

^h Infectious Disease Section   (United States)

ⁱ UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^j CENTER FOR BIOSTATISTICS IN AIDS RESEARCH   (United States)

^k DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^l UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

more..

Author keywords

carbapenem resistant Enterobacteriaceae; colistin; Klebsiella pneumoniae; mortality; ST258

Indexed keywords

ANTIINFECTIVE AGENT; BETA LACTAMASE; CARBAPENEM DERIVATIVE; COLISTIN;

AGED; ANTIBIOTIC RESISTANCE; CLASSIFICATION; COMORBIDITY; DRUG EFFECTS; FEMALE; GENETICS; HUMAN; KAPLAN MEIER METHOD; KLEBSIELLA INFECTION; KLEBSIELLA PNEUMONIAE; MALE; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; MIDDLE AGED; MORTALITY; PHYLOGENY; PROPORTIONAL HAZARDS MODEL;

AGED; ANTI-BACTERIAL AGENTS; BETA-LACTAM RESISTANCE; BETA-LACTAMASES; CARBAPENEMS; COLISTIN; COMORBIDITY; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; KLEBSIELLA INFECTIONS; KLEBSIELLA PNEUMONIAE; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; PHYLOGENY; PROPORTIONAL HAZARDS MODELS;

EID: 85021679212     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/ciw805     Document Type: Article

References (29)

1. Munoz-Price LS, Poirel L, Bonomo RA, et al. Clinical epidemiology of the global expansion of Klebsiella pneumoniae carbapenemases. Lancet Infect Dis 2013; 13:785–96.
2. van Duin D, Perez F, Rudin SD, et al. Surveillance of carbapenem-resistant Klebsiella pneumoniae: tracking molecular epidemiology and outcomes through a regional network. Antimicrob Agents Chemother 2014; 58:4035–41.
3. van Duin D, Kaye KS, Neuner EA, Bonomo RA. Carbapenem-resistant Enterobacteriaceae: a review of treatment and outcomes. Diagn Microbiol Infect Dis 2013; 75:115–20.
4. Qureshi ZA, Hittle LE, O’Hara JA, et al. Colistin-resistant Acinetobacter baumannii: beyond carbapenem resistance. Clin Infect Dis 2015; 60:1295–303.
5. Tumbarello M, Viale P, Viscoli C, et al. Predictors of mortality in bloodstream infections caused by Klebsiella pneumoniae carbapenemase-producing K. pneumoniae: importance of combination therapy. Clin Infect Dis 2012; 55:943–50.
6. van Duin D, Doi Y. Outbreak of colistin-resistant, carbapenemase-producing Klebsiellapneumoniae:areweattheendoftheroad?JClinMicrobiol2015;53:3116–7.
7. van Duin D, Cober E, Richter SS, et al. Residence in skilled nursing facilities is associated with tigecycline nonsusceptibility in carbapenem-resistant Klebsiella pneumoniae. Infect Control Hosp Epidemiol 2015; 36:942–8.
8. van Duin D, Cober E, Richter SS, et al. Impact of therapy and strain type on outcomes in urinary tract infections caused by carbapenem-resistant Klebsiella pneumoniae. J Antimicrob Chemother 2015; 70:1203–11.
9. van Duin D, Cober ED, Richter SS, et al. Tigecycline therapy for carbapenem-resistant Klebsiella pneumoniae (CRKP) bacteriuria leads to tigecycline resistance. Clin Microbiol Infect 2014; 20:O1117–1120.
10. Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing; Twenty-Second Informational Supplement. CLSI document M100-S22. Vol 32. Wayne, PA: Clinical and Laboratory Standards I, 2012.
11. Clinical and Laboratory Standards Institute. Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically; Approved Standard-Tenth Edition. CLSI document M07-A10. Wayne, PA: Clinical and Laboratory Standards I, 2015.
12. European Committee on Antimicrobial Susceptibility Testing. Breakpoint tables for interpretation of MICs and zone diameters, version 60. 2016. Available at: http://www.eucast.org. Accessed 1 June 2016.
13. Tenover FC, Williams PP, Stocker S, et al. Accuracy of six antimicrobial susceptibility methods for testing linezolid against staphylococci and enterococci. J Clin Microbiol 2007; 45:2917–22.
14. Lascols C, Hackel M, Marshall SH, et al. Increasing prevalence and dissemination of NDM-1 metallo-beta-lactamase in India: data from the SMART study (2009). J Antimicrob Chemother 2011; 66:1992–7.
15. Viau RA, Hujer AM, Marshall SH, et al. “Silent” dissemination of Klebsiella pneumoniae isolates bearing K. pneumoniae carbapenemase in a long-term care facility for children and young adults in northeast Ohio. Clin Infect Dis 2012; 54:1314–21.
16. Endimiani A, Hujer AM, Perez F, et al. Characterization of blaKPC-containing Klebsiella pneumoniae isolates detected in different institutions in the eastern USA. J Antimicrob Chemother 2009; 63:427–37.
17. Xavier BB, Lammens C, Ruhal R, et al. Identification of a novel plasmid-mediated colistin-resistance gene, mcr-2, in Escherichia coli, Belgium, June 2016. Euro Surveill 2016; 21.
18. Chow JW, Yu VL. Combination antibiotic therapy versus monotherapy for gram-negative bacteraemia: a commentary. Int J Antimicrob Agents 1999; 11:7–12.
19. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987; 40:373–83.
20. Hindler JA, Humphries RM. Colistin MIC variability by method for contemporary clinical isolates of multidrug-resistant gram-negative bacilli. J Clin Microbiol 2013; 51:1678–84.
21. American Society for Microbiology. White Paper on the Emergence of mcr-1 Plasmid-Mediated Colistin Resistance. Available at: https://www.asm.org/index.php/component/content/article/93-policy/94613-colistinres-10–16. Accessed 30 October 2016.
22. Giacobbe DR, Del Bono V, Trecarichi EM, et al. Risk factors for bloodstream infections due to colistin-resistant KPC-producing Klebsiella pneumoniae: results from a multicenter case-control-control study. Clin Microbiol Infect 2015; 21:1106.e1–8.
23. Kaye KS, Harris AD, Samore M, Carmeli Y. The case-case-control study design: addressing the limitations of risk factor studies for antimicrobial resistance. Infect Control Hosp Epidemiol 2005; 26:346–51.
24. Marchaim D, Chopra T, Pogue JM, et al. Outbreak of colistin-resistant, carbapenem-resistant Klebsiella pneumoniae in metropolitan Detroit, Michigan. Antimicrob Agents Chemother 2011; 55:593–9.
25. Wright MS, Suzuki Y, Jones MB, et al. Genomic and transcriptomic analyses of colistin-resistant clinical isolates of Klebsiella pneumoniae reveal multiple pathways of resistance. Antimicrob Agents Chemother 2015; 59:536–43.
26. Liu YY, Wang Y, Walsh TR, et al. Emergence of plasmid-mediated colistin resistance mechanism MCR-1 in animals and human beings in China: a microbiological and molecular biological study. Lancet Infect Dis 2016; 16:161–8.
27. McGann P, Snesrud E, Maybank R, et al. Escherichia coli harboring mcr-1 and blaCTX-M on a novel IncF plasmid: first report of mcr-1 in the United States. Antimicrob Agents Chemother 2016; 60:4420–1.
28. Castanheira M, Griffin MA, Deshpande LM, Mendes RE, Jones RN, Flamm RK. Detection of mcr-1 among Escherichia coli clinical isolates collected worldwide as part of the SENTRY antimicrobial surveillance program during 2014–2015. Antimicrob Agents Chemother 2016; 60:5623–4.
29. Guh AY, Bulens SN, Mu Y, et al. Epidemiology of carbapenem-resistant Enterobacteriaceae in 7 US communities, 2012–2013. JAMA 2015; 314:1479–87.